Advertisement
Advertisement
U.S. Markets open in 6 hrs 58 mins
Advertisement
Advertisement
Advertisement
Advertisement

Xilio Therapeutics, Inc. (XLO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4000-0.2000 (-7.69%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6000
Open2.7000
Bid2.3000 x 900
Ask2.7800 x 800
Day's Range2.3600 - 2.7000
52 Week Range2.3600 - 27.9500
Volume54,595
Avg. Volume38,030
Market Cap65.925M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-107.1570
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.00
  • GlobeNewswire

    Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

    WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 2:30 p.m. ET. A live webcast will be available in the Investors and Media section of the Xilio Therape

  • GlobeNewswire

    Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

    WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Stacey Davis has been appointed as chief business officer to further the company’s corporate and business development strategy that will be central to its next stage of growth. “As an accomplished life science leader, Stacey brings significant strategic business experience building

  • GlobeNewswire

    Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

    Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plans to submit IND for XTX301, a tumor-selective IL-12, in second half of 2022 Strong financial position with $177 million in cash and cash equivalents as of March 31, 2022, with cash runway anticipated into first half of 2024 WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechn

Advertisement
Advertisement